Island Pharmaceuticals Ltd has released a press release.
FDA meeting request lodged for Galidesivir
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- Preliminary Final Report
- Options exercise from existing substantial shareholder
- Completion of Galidesivir transaction
- Portfolio expansion achieved with acquisition of Galidesivir
- Successful Phase 2 clinical trial of ISLA-101
Later from Island Pharmaceuticals
- FDA Meeting request granted
- US FDA Type C meeting briefing document submitted
- FDA confirms response timing for Galidesivir
- FDA agrees Animal Rule pathway and PRV eligibility
- Island engages advisers to advance biodefence strategy
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals